Bioburden Testing Market Revenue Opportunities in Biotechnology Industry 2019
ID: 1717485
The bioburden testing market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4%
(firmenpresse) - According to the new market research report "Bioburden Testing Market by Product (Consumables, Instrument (PCR, Microscope)), Test (Anerobic, Mold/Fungi, Aerobic, Spore), Application (Raw Material, Medical Devices, Sterility Testing), End User (Pharma, Biotechnology, CMO) - Global Forecast to 2023", published by MarketsandMarkets™, the Bioburden Testing Market is projected to reach USD 1,103 million by 2023 from USD 614 million in 2018, at a CAGR of 12.4% during the forecast period.
The growth in this market is mainly driven by the growth in the medical devices, pharmaceutical, and biotechnology industries; rising safety concerns related to food and beverage products; and the increasing number of product recalls due to microbial contamination.
Don’t miss out on business opportunities in Bioburden Testing Market.
Download an Illustrative overview of the report @
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=17983056
Raw material testing segment to register the highest growth in the bioburden testing applications market during the forecast period.
By application, the Bioburden Testing Market is segmented into raw material testing, medical device testing, in-process material testing, sterilization validation testing, and equipment cleaning validation. In 2018, the raw material testing segment is expected to witness the highest growth rate during the forecast period. Growth in this segment is likely to be driven by the rising quality standards to ensure the safety of finished products.
Browse in-depth TOC on "Bioburden Testing Market"
78 - Tables
33 – Figures
129 - Pages
Request Free Sample Pages @
https://www.marketsandmarkets.com/requestsampleNew.asp?id=17983056
Contract manufacturing organizations to be the fastest-growing end-user segment of the Bioburden Testing Market
On the basis of end user, the Bioburden Testing Market is segmented into pharmaceutical and biotechnology companies, medical device manufacturers, contract manufacturing organizations (CMOs), manufacturers of food & beverage and agricultural products, and microbial testing laboratories. The CMOs segment is expected to grow at the highest CAGR during the forecast period owing to the increasing outsourcing of manufacturing processes from pharmaceutical and biotechnology companies to CMOs.
North America will continue to dominate the Bioburden Testing Market in the forecast period
On the basis of region, the Bioburden Testing Market is segmented into North America, Europe, Asia, and the RoW. In 2018, North America is expected to account for the largest share of the market, followed by Europe. Growth in the pharmaceutical and biotechnology industries, strong trend of R&D investments in life sciences research, and increasing government support for pharmaceutical and biotechnology companies are the major factors driving market growth in North America. However, the Asian market is expected to grow at the highest CAGR during the forecast period, primarily due to the expansion of key market players in emerging Asian countries, increasing expenditure on life science research, and the increasing trend of pharmaceutical outsourcing to Asian countries.
The Bioburden Testing Market is competitive in nature, with the presence of several large and small players. Charles River (US), Merck KGaA (Germany), SGS SA (Switzerland), WuXi AppTec (China), Becton, Dickinson and Company (US), NAMSA (US), Nelson Laboratories, LLC (US), Thermo Fisher Scientific (US), biomérieux SA (France), and Pacific BioLabs (US) are some of the leading payers in the Bioburden Testing Market.
Weitere Infos zu dieser Pressemeldung:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales(at)marketsandmarkets.com
Datum: 29.04.2019 - 11:45 Uhr
Sprache: Deutsch
News-ID 1717485
Anzahl Zeichen: 3958
Kontakt-Informationen:
Ansprechpartner: Shelly Singh
Stadt:
Northbrook
Telefon: 18886006441
Kategorie:
Biotechnologie
Meldungsart: Finanzinformation
Versandart: Veröffentlichung
Freigabedatum: 29.04.2019
Diese Pressemitteilung wurde bisher 354 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bioburden Testing Market Revenue Opportunities in Biotechnology Industry 2019"
steht unter der journalistisch-redaktionellen Verantwortung von
MnM (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
The growth of this market is mainly driven by factors such as the increasing R&D expenditure in the pharmaceutical industry, increasing focus on miniaturization, technological advancements, and growing prevalence of diseases. The report "Microplate Systems Market by Product (Microplate R
3D Cell Culture Market : Regenerative Medicine to Offer Global Growth In Coming Years ...
A 3D cell culture is an artificially created environment in which biological cells are permitted to grow or interact with their surroundings in all three dimensions. Factors such as rising focus on developing alternative methods for animal testing, funding initiatives from government and private
Immuno Oncology Assays : Research Application Transforming the Industrial Business ...
What the Immuno Oncology Assays Market looks like? Growth in Immuno Oncology Assays Market is largely driven by factors such as the increasing adoption of targeted therapy over traditional therapy and the increasing demand for mAbs. According to the new market research report "Immuno Onco
Weitere Mitteilungen von MnM
Roche präsentierte Datenmaterial von Caprion Bioscience zu zielgerichteter Massenspektrometrie für klinische Proteomik ...
Caprion Biosciences (https://c212.net/ c/link/?t=0&l=en&o=2446464-1&h=3209617121&u=http%3A%2F%2Fwww.caprion. com%2F&a=Caprion+Biosciences) ist erfreut, den Abschluss einer in Zusammenarbeit durchgeführten Studie bekanntzugeben, in der Massenspektrometrie zur Quantifizierung vo
Nächstes Food Fraud Seminar am 17. Mai 2019 ...
Täglich wird über neue Fälle von Lebensmittelverfälschung berichtet. Unternehmen, die gemäß eines GFSI-anerkannten Standards wie IFS zertifiziert sind, müssen dafür Sorge tragen, dass sowohl die eingehenden Waren als auch deren Produkte authentisch sind. Doch worauf achtet ein Auditor? Wo li
TAU BIO-LOGIC kündigt die Humanisierung des monoklonalen Antikörpers Picomolar Affinity gegen das TauC3-Protein zur Behandlung von Alzheimer und progressiver supranuklearer Lähmung an ...
TAU BIO-LOGIC CORP. gab heute bekannt, dass sie in Zusammenarbeit mit der britischen Gruppe LifeArc erfolgreich einen monoklonalen Antikörper (TBL-100) humanisiert hat, der gegen das C-terminale trunkierte Tau (tauC3) gerichtet ist. TAU BIO-LOGIC entwickelt TBL-100 zur Behandlung von Alzheimer
Düngeverordnung ? wir zeigen Ihnen die Lösung auf der Agra 2019! ...
Die Düngeverordnung verspricht positive Ziele wie die Erhöhung der Effizienz von Düngungen, Schutz von Gewässern und eine Reduktion von Ammoniakemissionen. Doch die Kehrseite für Landwirte ist immens. Sehen wir schon allein davon ab, dass Lagerkapazitäten erhöht oder betrieblich ausgelagert w
